166 related articles for article (PubMed ID: 37900167)
1. Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool.
Suhail M; AlZahrani WM; Shakil S; Tarique M; Tabrez S; Zughaibi TA; Rehan M
Front Pharmacol; 2023; 14():1236173. PubMed ID: 37900167
[TBL] [Abstract][Full Text] [Related]
2. Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3Kγ Kinase Using Computational Methods.
Rehan M; Mahmoud MM; Tabrez S; Hassan HMA; Ashraf GM
Anticancer Res; 2020 Aug; 40(8):4547-4556. PubMed ID: 32727785
[TBL] [Abstract][Full Text] [Related]
3. Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells.
Zhang HW; Hu JJ; Fu RQ; Liu X; Zhang YH; Li J; Liu L; Li YN; Deng Q; Luo QS; Ouyang Q; Gao N
Sci Rep; 2018 Jul; 8(1):11255. PubMed ID: 30050147
[TBL] [Abstract][Full Text] [Related]
4. Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses.
Jia L; Wang L; Jiang Y; Xu L; Cai Y; Chen Y; Jin J; Sun H; Zhu J
Comput Biol Med; 2022 Aug; 147():105642. PubMed ID: 35635904
[TBL] [Abstract][Full Text] [Related]
5. Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors.
Al Hasan M; Sabirianov M; Redwine G; Goettsch K; Yang SX; Zhong HA
J Mol Graph Model; 2023 Jun; 121():108433. PubMed ID: 36812742
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms.
Zhu J; Ke K; Xu L; Jin J
RSC Adv; 2019 Jun; 9(35):20207-20215. PubMed ID: 35546906
[TBL] [Abstract][Full Text] [Related]
7. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches.
Mohd Rehan
J Mol Graph Model; 2015 Nov; 62():226-234. PubMed ID: 26500112
[TBL] [Abstract][Full Text] [Related]
8. Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.
Rehan M
PLoS One; 2019; 14(6):e0219180. PubMed ID: 31247018
[TBL] [Abstract][Full Text] [Related]
9. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
[TBL] [Abstract][Full Text] [Related]
11. Water Molecules Increases Binding Affinity of Natural PI3Kγ Inhibitors Against Cancer.
Sharma P; Shukla A; Kalani K; Dubey V; Srivastava SK; Luqman S; Khan F
Curr Comput Aided Drug Des; 2015; 11(4):304-20. PubMed ID: 26603929
[TBL] [Abstract][Full Text] [Related]
12. Flavonoids and PI3K/Akt/mTOR Signaling Cascade: A Potential Crosstalk in Anticancer Treatment.
Ul Islam B; Suhail M; Khan MS; Ahmad A; Zughaibi TA; Husain FM; Rehman MT; Tabrez S
Curr Med Chem; 2021; 28(39):8083-8097. PubMed ID: 34348607
[TBL] [Abstract][Full Text] [Related]
13. Computational study reveals substituted benzimidazole derivatives' binding selectivity to PI3Kδ and PI3Kγ.
Zhang NN; Bai X; Zhao SS; Zheng XM; Tang L; Yang SG; Zhang JQ
J Mol Model; 2022 Apr; 28(5):123. PubMed ID: 35438328
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Natural Compounds in Flavonoids for Their Potential Inhibition of Cancer Therapeutic Target MEK1 Using Computational Methods.
AlZahrani WM; AlGhamdi SA; Zughaibi TA; Rehan M
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215307
[TBL] [Abstract][Full Text] [Related]
15. In-silico & In-vitro Identification of Structure-Activity Relationship Pattern of Serpentine & Gallic Acid Targeting PI3Kγ as Potential Anticancer Target.
Sharma P; Shukla A; Kalani K; Dubey V; Luqman S; Srivastava SK; Khan F
Curr Cancer Drug Targets; 2017; 17(8):722-734. PubMed ID: 28359246
[TBL] [Abstract][Full Text] [Related]
16. Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies.
Bhaskar BV; Rammohan A; Babu TM; Zheng GY; Chen W; Rajendra W; Zyryanov GV; Gu W
Sci Rep; 2021 Jun; 11(1):12150. PubMed ID: 34108504
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer-signaling PI3K/AKT/mTOR pathway.
Rehan M; Bajouh OS
J Cell Biochem; 2019 Feb; 120(2):1328-1339. PubMed ID: 30298630
[TBL] [Abstract][Full Text] [Related]
18. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors.
Zhu J; Li K; Yu L; Chen Y; Cai Y; Jin J; Hou T
Med Res Rev; 2021 May; 41(3):1599-1621. PubMed ID: 33300614
[TBL] [Abstract][Full Text] [Related]
19. Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach.
Abd Emoniem N; Mukhtar RM; Ghaboosh H; Elshamly EM; Mohamed MA; Elsaman T; Alzain AA
SAR QSAR Environ Res; 2023 Feb; 34(2):163-182. PubMed ID: 36853097
[TBL] [Abstract][Full Text] [Related]
20. mTOR Targeted Cancer Chemoprevention by Flavonoids.
Badar Ul Islam ; Khan MS; Husain FM; Rehman MT; Zughaibi TA; Abuzenadah AM; Urooj M; Kamal MA; Tabrez S
Curr Med Chem; 2021; 28(39):8068-8082. PubMed ID: 33167824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
